Search Patents
  • Pneumococcal fimbrial protein A
    Patent number: 5422427
    Abstract: The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: June 6, 1995
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Harold Russell, Jacquelyn Sampson, Steven P. O'Connor
  • Kainate-binding, human CNS receptors of the EAA2 family
    Patent number: 5494792
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commerical significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: February 27, 1996
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Rajender Kamboj, Stephen L. Nutt, Lee Shekter, Michael A. Wosnick
  • Mutant microbial .alpha.-amylases with increased thermal, acid and/or alkaline stability
    Patent number: 5364782
    Abstract: Thermostable and acid stable .alpha.-amylases are provided as expression products of genetically engineered .alpha.-amylase genes isolated from microorganisms, preferably belonging to the class of Bacilli. Both chemical and enzymatic mutagenesis methods are e.g. the bisulphite method and enzymatic misincorporation on gapped heteroduplex DNA. The mutant .alpha.-amylases have superior properties, e.g. improved thermostability over a broad pH range, for industrial application in starch processing and textile desizing.
    Type: Grant
    Filed: November 29, 1990
    Date of Patent: November 15, 1994
    Assignees: Gist-Brocades N.V., Plant Genetic Systems N.V.
    Inventors: Wilhelmus J. Quax, Yves Laroche, Adrianus W. H. Vollebregt, Patrick Stanssens, Marc Lauwereys
  • Recombinant trichosanthin and coding sequence
    Patent number: 5128460
    Abstract: Disclosed are the entire protein and nucleic acid coding sequences for unprocessed and mature trichosanthin protein from Trichosanthes kirilowii. A recombinant trichosanthin protein produced from the coding sequence, and the trichosanthin protein with amino-terminal and/or carboxy-terminal extensions are also described. Primers derived from the coding sequence are disclosed for use in obtaining the coding sequences of ribosome-inactivating-proteins which have regions of amino acid sequence identical to those of trichosanthin. Further, a multigene family of ribosome-inactivating-protein encoding genes of Trichosanthes kirilowii is also described.
    Type: Grant
    Filed: April 4, 1990
    Date of Patent: July 7, 1992
    Assignee: Genelabs Incorporated
    Inventors: Michael Piatak, Jr., Theresa P. Chow, Kirk Fry
  • Chrysanthemyl diphosphate synthase, corresponding genes and use in pyrethrin synthesis
    Patent number: 5443978
    Abstract: This invention provides a purified chrysanthemyl diphosphate synthase (CDS), a method for the purification of CDS from Chrysanthemum cinerariaefolium, and an amino acid sequence of the isolated CDS. Also provided is a cDNA encoding the CDS, a nucleotide sequence of the CDS gene, and a derived amino acid sequence of the encoded CDS protein. The CDS gene is useful in the enzymatic production of the natural stereospecific configuration of chrysanthemyl derivatives which are useful for the synthesis of pyrethrins, pyrethroids, derivatives thereof, as well as other classes of metabolites.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: August 22, 1995
    Assignee: Agridyne Technologies, Inc.
    Inventors: Suzanne R. Ellenberger, Galen D. Peiser, Russell N. Bell, Charles E. Hussey, Jr., Donna M. Shattuck-Eidens, Bradley D. Swedlund
  • Modified 7S legume seed storage proteins
    Patent number: 5003045
    Abstract: The present invention discloses plant cells which contain modified 7S legume seed storage protein. Modification of 7S seed storage proteins which are expressible in plant cells and transformation of such genes into plant cells is also taught. Furthermore, methods and DNA molecules useful for producing plant cells containing modified 7S seed storage proteins are also disclosed. The invention is exemplified by insertion of an oligonucleotide encoding 15 amino acid residues, including 6 methionines, into a Phaseolus vulgaris phaseolin gene, thereby tripling its content of sulfur-containing amino acids.
    Type: Grant
    Filed: August 29, 1986
    Date of Patent: March 26, 1991
    Assignee: Lubrizol Genetics, Inc.
    Inventor: Leslie M. Hoffman
  • Affinity purification of plasminogen activator inhibitor I using a modified urokinase
    Patent number: 5073626
    Abstract: A method of purifying PAI-1 from a biological fluid source, e.g. conditioned media of Hep G2 or HT 1080 cells, containing PAI-1 is disclosed, which comprises subjecting the biological fluid to a modified urokinase affinity absorbent, e.g. anhydrourokinase ligand bound to a CNBr-activated agarose gel or urokinase mutated at amino acid position 356 from Ser to Gly and bound to the gel, and then eluting PAI-1 from said affinity absorbent. A method of stabilizing and/or activating PAI-1 is also disclosed, which comprises complexing PAI-1 with vitronectin.
    Type: Grant
    Filed: June 4, 1990
    Date of Patent: December 17, 1991
    Assignee: Monsanto Company
    Inventor: Tze-Chein Wun
  • DNA fragment encoding a polypeptide having nitrile hydratase activity, a transformant containing the gene and a process for the production of amides using the transformant
    Patent number: 5753472
    Abstract: The present invention has disclosed the amino acid sequence and nucleotide sequence of the .alpha.- and .beta.-subunits of two types of nitrile hydratase derived from Rhodococcus rhodochrous J-1. The DNA fragment encoding nitrile hydratase is inserted into an expression vector and the recombinant vector is used for transformation. The transformant contains multiple copies of the gene and can produce much higher level of nitrile hydratase compared with conventionally used microorganisms.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 19, 1998
    Assignee: Nitto Chemical Industry Co. Ltd.
    Inventors: Hideaki Yamada, Toru Nagasawa, Teruhiko Beppu, Sueharu Horinouch, Makoto Nishiyama
  • Vertebrate apoptosis gene: compositions and methods
    Patent number: 5646008
    Abstract: The invention relates generally to compositions of and methods for obtaining and using a polypeptide other than BCL-2 that affects programmed vertebrate cell death. The invention relates as well to polynucleotides encoding those polypeptides, recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant polypeptides. The invention further provides methods for using the isolated, recombinant polypeptides in assays designed to select and improve substances capable of altering programmed cell death for use in diagnostic, drug design and therapeutic applications.
    Type: Grant
    Filed: June 22, 1993
    Date of Patent: July 8, 1997
    Assignee: The Regent of the University of Michigan
    Inventors: Craig B. Thompson, Lawrence H. Boise, Gabriel Nunez
  • Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
    Patent number: 5169936
    Abstract: A process for the purification of proteins from solutions containing contaminants of similar net charge and molecular weight is provided, comprising contacting a solution containing the desired protein with an immobilized metal affinity chromatography resin in a buffer containing a low concentration of a weak ligand for the chelant of the resin. The adsorbed protein is then eluted using a buffer having a high concentration of the same weak ligand, e.g., Tris. Particularly preferred features employ agarose-iminodiacetic acid resins having copper cations and are especially useful in obtaining preparations of homogeneous, stable rsT4 proteins.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: December 8, 1992
    Assignee: Biogen, Inc.
    Inventors: Mark A. Staples, Christopher A. Pargellis
  • Isolation of Hepatitis B surface antigen from transformed yeast cells
    Patent number: 5462863
    Abstract: A method for recovering hepatitis B surface antigen protein from transformed yeast cells including the steps of (i) obtaining an aqueous homogenate of the yeast cells; (ii) enriching the hepatitis B surface antigen protein in the homogenate with a protein-aggregating reagent to form a precipitate which contains hepatitis B surface antigen protein; (iii) dissolving the precipitate in a buffer to form a suspension; and (iv) post-homogenizing the suspension to obtain a 10% to 50% increase in yield of the hepatitis B surface antigen protein as calculated based on a yield achieved without performing the post-homogenizing step.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: October 31, 1995
    Assignee: Development Center for Biotechnology
    Inventors: Jih-Han Hsieh, Shu-Ching Shih, Wei-Kuang Chi, Yi-Ding Chu, Ae-Ning Lin
  • Method for purifying a gene-expression product produced by recombinant DNA technique
    Patent number: 4902783
    Abstract: There is disclosed a method for purifying a gene-expression product produced by recombinant DNA technique which comprises a specific sequence of steps including adsorption treatment with silica gel, adsorption treatment with activated carbon, at least twice density gradient centrifugation and at least twice equilibrium density gradient centrifugation. The method of the present invention is very effective to remove allergen from gene-expression products contaminated therewith, enabling highly purified gene-expression products to be produced on a large scale.
    Type: Grant
    Filed: June 15, 1987
    Date of Patent: February 20, 1990
    Assignee: The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Hideo Goda, Toshiyuki Akiyama, Akihisa Takamizawa, Iwao Yoshida, Takeo Konobe, Keisuke Takaku
  • Immuno-polymerase chain reaction system for antigen detection
    Patent number: 5665539
    Abstract: A novel system and method for sensitive antigen detection. The system utilizes immuno-polymerase chain reaction in which a specific biotinylated nucleic acid molecule is used as the marker. The biotinylated marker is attached to antigen-antibody complex through a streptavidin-protein A chimeric protein that possesses tight and specific binding affinity both for biotin and immunoglobulin G. A segment of the attached biotinylated marker is amplified by polymerase chain reactions with appropriate primers and the polymerase chain reaction products are detected by agarose gel electrophoresis. The method can detect any antigen and has a greater sensitivity than any existing antigen detection system.
    Type: Grant
    Filed: October 4, 1993
    Date of Patent: September 9, 1997
    Assignee: The Regents of the University of California
    Inventors: Takeshi Sano, Charles R. Cantor, Cassandra L. Smith
  • Hybrid cells producing an antigen characteristic of the hepatitis B virus obtained from hepatocytes and established monkey cells, a process for obtaining these hybrid cells and their application to the production of the aforesaid antigen
    Patent number: 5112748
    Abstract: The invention concerns hybrid cells transformed or transformable by a cloned DNA containing the sequence coding for the antigen HBs. They are characterized in that they contain, on the one hand, at least a part of the genetic heritage of monkey hepatocyte cells and, on the other hand, a genetic marker permitting them to grow in a selective medium or one containing an active principle normally lethal to the VERO cells from which the hybrid is derived, but able to be inactivated by the polypeptide expressed by the said genetic marker.
    Type: Grant
    Filed: February 19, 1987
    Date of Patent: May 12, 1992
    Assignee: Institut Pasteur and Centre National de la Recherche Scientifique
    Inventors: Nicole Chenciner, Jean-Francois Houssais
  • Macrophage inflammatory protein-3 and -4
    Patent number: 5504003
    Abstract: There is disclosed a human macrophage inflammatory protein-3 (MIP-3) and a human macrophage inflammatory protein-4 (MIP-4) polypeptides and DNA (RNA) encoding such polypeptides. There is also provided a procedure for producing such polypeptides by recombinant techniques and for producing antibodies against such polypeptides. In the invention there is also provided antagonist/inhibitors against such polypeptides which inhibit the functioning of such polypeptides. Another aspect of the invention provides a combination of the polypeptides of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptides for the treatment of various associated diseases.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: April 2, 1996
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Steven Ruben
  • Conotoxins I
    Patent number: 5432155
    Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: July 11, 1995
    Assignees: The Salk Institute For Biological Studies, University of Utah Research Foundation
    Inventors: Baldomero M. Olivera, Jean E. F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres
  • Method for the purification of factor XIII by affinity chromatography
    Patent number: 5047506
    Abstract: The invention relates to a method for the purification of the a subunit of factor XIII by affinity chromatography, to a therapeutic composition containing the latter, and to the use of the therapeutic composition.Factor XIII has hitherto been purified either by methods which are technically very elaborate or else by use of toxic affinity chromatography materials. The invention has the aim of providing an improved method for the purification of the a subunit of factor XIII.Factor XIII is obtained according to the invention by a method in which the a subunit of factor XIII is reversibly bound to a matrix suitable for disulfide exchange reactions and is removed from the matrix by reaction with a reducing agent. The method according to the invention makes it possible to provide the biologically active a subunit of factor XIII in high purity.
    Type: Grant
    Filed: March 9, 1989
    Date of Patent: September 10, 1991
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hartmut Lobermann, Jurgen Romisch, Werner Stuber
  • Low pH pharmaceutical compositions of recombinant .beta.-interferon
    Patent number: 5004605
    Abstract: Stable pharmaceutical compositions suitable for parenteral administration to mammals are prepared which are in a pH range of about 2 to about 4 and comprise a therapeutically effective amount of a recombinant interferon-.beta. protein (IFN-.beta.) dissolved in an inert carrier medium comprising as a stabilizer/solubilizer an effective amount either of glycerol or of polyethylene glycol polymers having an average molecular weight from about 190 to about 1600 daltons. Further disclosed and claimed are methods for extracting IFN-.beta. from a microbial host transformed to produce it and then purifying and formulating said IFN-.beta. and methods for screening for other polyhydric non-detergent stabilizer/solubilizers or combinations thereof as solubilizer/stabilizers for pharmaceutical compositions of IFN-.beta..
    Type: Grant
    Filed: December 10, 1987
    Date of Patent: April 2, 1991
    Assignee: Cetus Corporation
    Inventors: Susan Hershenson, Jody Thomson
  • Human .beta.2 integrin .alpha. subunit
    Patent number: 5766850
    Abstract: DNA encoding a novel human .beta..sub.2 integrin .alpha. subunit polypeptide, designated .alpha..sub.d, is disclosed along with methods and materials for production of the same by recombinant procedures. Fusion proteins are also disclosed which include extracellular .alpha..sub.d protein fragments, .alpha..sub.d I domain fragments or full length .alpha..sub.d polypeptides and human immunoglobulin constant regions. Binding molecules specific for .alpha..sub.d are also disclosed as useful for modulating the biological activities of .alpha..sub.d. DNA from other species which show homology to human .alpha..sub.d encoding sequences are also disclosed.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: June 16, 1998
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
    Patent number: 5266317
    Abstract: Genes encoding insect-specific paralytic neurotoxins, particularly those of insect-parasitic mites, including Pyemotes, are described. Recombinant DNA molecules in which the neurotoxin coding sequences are placed under the control of heterologous promoters are also described. Such molecules are useful for the development of biological insect control agents which produce insect-toxic levels of the neurotoxin. Specifically described are genetically altered baculoviruses which produce insect-specific paralytic neurotoxins and which display improved toxic effect on insects. Insect-toxic compositions are also provided. Methods of insect control using these neurotoxin genes, methods for production of neurotoxins in cells, and methods of production of insect control agents are described.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: November 30, 1993
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Michael D. Tomalski, Lois K. Miller
Narrow Results

Filter by US Classification